Skip to content

Pilot Study of Discarded Blastocysts

Prospective Observational Pilot Study of Discarded Blastocysts: a Molecular Approach to Uncovering Hidden Reproductive Potential

Status
Not yet recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07429097
Acronym
DECODE
Enrollment
150
Registered
2026-02-24
Start date
2026-02-01
Completion date
2027-05-01
Last updated
2026-02-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infertility (IVF Patients)

Keywords

blastocyst, aneuploidy, inner cell mass, PGT-A, trophectoderm

Brief summary

The goal of this observational study is to determine multiomics patterns related to global embryo quality to help overcome the limitations of conventional embryo quality assessment. The main question it aims to answer is: • Do discarded blastocysts that reach the blastocyst stage (days 5-6) show characteristic multiomics profiles which correlate with chromosomal abnormalities, providing insights into embryo viability? For that, patients undergoing an IVF treatment will be asked to donate their clinically discarded 5/6-day embryos (those that do not meet clinical criteria to be used for reproductive purposes). Participation in the study will not interfere with the planned IVF treatment. Patient participation is limited to signature of the informed consent to donate embryos and no other study-specific procedures will be performed on participants.

Detailed description

In vitro fertilization has advanced infertility treatment, but accurately assessing embryo viability remains challenging because conventional selection methods may miss subtle molecular indicators of developmental potential. Increasing evidence shows that some embryos discarded based on morphology or developmental timing may be chromosomally normal and possess favorable molecular traits, prompting interest in multiomics analysis as a more sensitive assessment tool. Studies have demonstrated that omics patterns can distinguish chromosomally normal from abnormal embryos and correlate with key indicators of developmental competence, such as morphology, arrest status, and implantation success, with high-potential blastocysts showing distinct developmental gene signatures. The blastocyst stage is particularly critical, as inner cell mass (ICM) and trophectoderm (TE) lineages diverge, and emerging data suggest these cell types exhibit different multiomics responses to chromosomal abnormalities. However, many prior studies relied on vitrified embryos, where cryopreservation may alter multiomic profiles. To address this limitation, this study focuses on fresh, non-vitrified blastocysts, offering a more accurate representation of embryos' intrinsic molecular states and developmental potential. Therefore, the aim of the present pilot study is to define multiomics patterns associated with euploidy, chromosomal abnormalities and embryo quality at the blastocyst stage. Once the study is approved by the competent Research Ethics Committee, the recruitment and selection of patients will follow. Every potential participant will be asked to sign the study informed consent. To comply with the study design and the proposed hypothesis, an estimated total number of 150 patients will be recruited to obtain around 200 discarded embryos. This is a prospective, descriptive, observational pilot study which will include all eligible discarded blastocysts donated by IVF patients from a single Norwegian centre. This site will be responsible for patients' recruitment and embryonic samples collection, while sample analysis will take place in a Central Laboratory in Spain. On day 5/6 of development, blastocysts that do not meet the standard clinical criteria to be transferred, will be donated to the study by the participants. Additionally, when possible, cumulus cells and sperm cells will also be collected. After embryo donation, 2 trophectoderm and 1 inner cell mass biopsies will be collected and analysed for multiomics profiling. Data exported from the medical records and source documents will be duly codified to protect the clinical and personal information of patients in accordance with the current legislation on data protection. This information will be exported to an internal database. Participants' involvement in the study will be limited to the consent; participants will not undergo any other study specific procedures.

Interventions

Donated discarded blastocysts (day 5/6) will undergo 2 TE biopsies and 1 ICM biopsy which will be analyzed for chromosomic status and multiomics profiles. Additional, when possible, cumulus cells and sper cells will also be analyzed. After donation of the discarded embryos, participants will follow their established IVF treatment.

Sponsors

Igenomix
Lead SponsorINDUSTRY
Oslo University Hospital
CollaboratorOTHER

Study design

Observational model
OTHER
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Age
20 Years to 42 Years
Healthy volunteers
No

Inclusion criteria

* Patients whose written informed consent approved by the Ethic Committee has been obtained, after having been duly informed of the nature of the study and voluntarily accepted to participate after being fully aware of the potential risks, benefits, and any discomfort involved. * Patients undergoing regular IVF/ICSI cycles with fresh oocytes and embryo culture to the blastocyst stage (day 5-6 after fertilization) * Patients' age will be between 20-42 years of age. * Patients without PGT-M or PGT-SR indication.

Exclusion criteria

* Patients who do not have at least one discarded blastocyst on day 5-6 of development. * Patients with discarded blastocysts that do not meet these criteria: * Presence of ICM * Non-degenerated

Design outcomes

Primary

MeasureTime frameDescription
Establishment of multiomics patterns associated with euploidy, chromosomal abnormalities and embryo quality at the blastocyst stage.1 day, corresponding to the Informed Consent signature date.Discarded embryos will be analyzed for multiomics and bioinformatic analysis will be applied to find multiomics patterns that correlate with euploidy, chromosomal abnormalities and embryo quality.

Secondary

MeasureTime frameDescription
Determination of the genetic constitution of different blastocyst compartments.1 day, corresponding to the Informed Consent signature date.Comparison of the genetic constitution of trophectoderm (TE) and inner cell mass (ICM) biopsies from the same blastocyst.
Determination of the incidence of chromosomally normal blastocysts with normal fertilization (2PN) that have been discarded due to poor morphology, slow development or cell degeneration.1 day, corresponding to the Informed Consent signature date.Chromosomic dotation of 2PN blastocysts that have been discarded (due to poor morphology, slow development or cell degeneration) will be analyzed for chromosomal status and the ratio of normal blastocysts will be calculated.
Determination of the incidence of chromosomally normal blastocysts in blastocysts with atypical fertilization (0PN, 1PN, 3PN).1 day, corresponding to the Informed Consent signature date.Chromosomic dotation of atypically fertilized blastocysts (0PN, 1PN, 2PN) will be analyzed and the ratio of chromosomically normal blastocysts will be calculated.
Exploration of the potential contamination of TE biopsies with cumulus and sperm cells and its possible impact on the accuracy of the results.1 day, corresponding to the Informed Consent signature date.Genetic analysis of the TE biopsies will be compared with the genetic analysis of cumulus cells and sperm cells for possible DNA contamination in the TE biopsy.
Correlation of embryo morphokinetics parameters with the TE and ICM chromosomal status.1 day, corresponding to the Informed Consent signature date.Genetic analysis of the TE and ICM biopsies will be compared with embryo morphokinetics parameters to find any correlations.
Correlation of embryo morphokinetics parameters with the TE and ICM multiomics profiles.1 day, corresponding to the Informed Consent signature date.Multiomics profiling of the TE and ICM biopsies will be compared with embryo morphokinetics parameters to find any correlations.
Correlation of sibling relatedness with multiomics profiles in cases with more than one embryo available per cycle1 day, corresponding to the Informed Consent signature date.When more than one embryo is discarded from the same cycle, they will be analysed to find a possible correlation between sibling relatedness and multiomics profiles.

Countries

Norway

Contacts

CONTACTCarlos Gómez De La Cruz, PhD
carlos.gomez@vitrolifegroup.com(+34) 963905310
CONTACTEsperanza Irles Vidal, PhD
esperanza.irles@vitrolifegroup.com
STUDY_CHAIRCarmen Rubio, PhD

Vicepresident R&D Genetic Services

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 25, 2026